Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study

Clinical activity after fingolimod cessation: disease reactivation or rebound?

(2018) J. Frau et al.   EUROPEAN JOURNAL OF NEUROLOGY

Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study

(2018) Konstantin Huhn et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis

(2018) Alan J Thompson et al.   LANCET

Defining response profiles after alemtuzumab

(2018) Heinz Wiendl et al.   NEUROLOGY

Activation of disease during therapy with alemtuzumab in 3 patients with multiple sclerosis

(2018) Thomas Wehrum et al.   NEUROLOGY

No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

(2018) Luca Prosperini et al.   JOURNAL OF NEUROLOGY

Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab

(2018) Raphaël Bernard-Valnet et al.   Multiple Sclerosis and Related Disorders

Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study

(2017) Hanne Marie Bøe Lunde et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy

(2017) Aiden Haghikia et al.   LANCET NEUROLOGY

Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod

(2017) Anna Członkowska et al.   Neurologia i Neurochirurgia Polska

Steering through complexity

(2016) Bruce A.C. Cree et al.   CURRENT OPINION IN NEUROLOGY

Personalised medicine for multiple sclerosis care

(2016) Arie Gafson et al.   Multiple Sclerosis Journal

Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment

(2016) Stacy Ellen Hatcher et al.   JAMA Neurology

Personalised medicine for multiple sclerosis care

(2016) Arie Gafson et al.   Multiple Sclerosis Journal

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Rebound of Disease Activity After Withdrawal of Fingolimod (FTY720) Treatment

(2012) Joachim B. Havla   ARCHIVES OF NEUROLOGY

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

(2012) Jeffrey A Cohen et al.   LANCET

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE